V
Vaccines/vaccination
neoplastic disease prevention,
523
Vagal stimulation, antiarrhythmia,
437
Vaginosis, bacterial,
201
Vagus nerve, cardiac effects,
437
Vancomycin,
179–180
Neisseria meningitidis meningitis,
197
Streptococcus pneumoniae meningitis,
197
Variability, clinical trials,
48
Varicella zoster virus infection,
213–215
Vascular endothelial growth factor (VEGF),
520
Vascular endothelial growth factor (VEGF) inhibitors,
520t,
521,
522f
Vascular smooth muscle cells, calcium channel blockers,
396
Vasculitis, drug-induced renal disease,
462
Vasoconstriction, drug action prolongation,
97
Vasodilators,
394–402
peripheral vascular disease,
402
Vasopressin,
599
portal pressure therapy,
549
Venlafaxine
generalised anxiety disorder,
335
therapeutic efficacy,
316
Venous thromboembolism
hormone replacement therapy,
604
oral combined contraceptive,
607–608
Ventilation, poisoning supportive treatment,
124
Ventricular fibrillation,
442
Ventricular outflow obstruction,
406
Ventricular premature beats,
442
Ventricular tachycardia,
442
Verotoxic
Escherichia coli,
198
Very-low-density lipoproteins (VLDLs) disorders,
444
Vibrio cholerae infection,
198
Viral hepatitis,
553–555 see also specific diseases
Viral infections,
213–222,
214t
adrenal steroid effects,
565
immunomodulatory drugs,
222
skin,
275 see also specific infections
Viridans group streptococci endocarditis,
196
Visceral larva migrans,
237t
Vitamin(s),
615–624
ethanol withdrawal,
147 see also specific vitamins
Vitamin B
1 (thiamine),
616
Vitamin B
6 (pyridoxine),
616
Vitamin B complex,
616–617 see also specific vitamins
Vitamin C (ascorbic acid),
617
Vitamin D deficiency,
619
primary biliary cirrhosis,
552
hyperlipidaemia treatment,
450
Vitamin K antagonists (VKA),
485–487
VKA (vitamin K antagonists),
485–487
VLDL (very-low-density lipoprotein) disorders,
444
Voluntary reporting, pharmacovigilance,
52
Von Willebrand's disease,
485